Company Profile

Guard Therapeutics International AB (publ), formerly A1M Pharma AB, is a Sweden-based company, which is active within the healthcare sector. The Company conducts development and commercialization of treatment and diagnostics based on the alpha-1-microglobulin (A1M) protein. The protein serves as a radical inhibitor, an antioxidant, a protector against free hemoglobin and a tissue repairer. A1M is a candidate for different therapeutic and diagnostic uses, such as alleviation of autoimmune diseases and stroke treatment. The Company works with the protein and conducts research at the Biomedical Center in Lund University, Sweden. The Company develops a drug for intravenous treatment of preeclampsia, a condition that can occur during pregnancy and can contribute to premature deliveries.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-08-07	SEK 1.386	+4.21%	860
26-08-06	SEK 1.330	+0.45%	7,656
26-08-05	SEK 1.324	-1.93%	23,840
26-08-04	SEK 1.350	-2.88%	1,620
26-08-03	SEK 1.390	-10.78%	43,556

Delayed Quote Nasdaq Stockholm

More quotes

Market Closed - Nasdaq Stockholm Other stock markets 12:00:00 2026-08-07 EDT			5-day change	1st Jan Change
1.386 ^SEK	+4.21%		-11.04%	-5.71%

07-26	Disruptive Pharma Holding Ab completed the acquisition of Guard Therapeutics International AB (OM:GUARD) in a reverse merger transaction in a transaction.	CI
07-17	Guard Therapeutics Gets Conditional Approval For Continued Listing	RE

07-26	Disruptive Pharma Holding Ab completed the acquisition of Guard Therapeutics International AB (OM:GUARD) in a reverse merger transaction in a transaction.	CI
07-17	Guard Therapeutics Gets Conditional Approval For Continued Listing	RE
07-17	Guard Therapeutics Secures Conditional Nasdaq Listing Approval Ahead of Disruptive Pharma Takeover	MT
06-12	Guard Therapeutics Initiates Divestment of GTX Platform	MT
06-11	Guard Therapeutics to Acquire Disruptive Pharma in Reverse Takeover	MT
06-11	Guard Therapeutics announces reverse takeover and planned name change	FW
06-09	Disruptive Pharma Holding Ab entered into a conditional agreement to acquire Guard Therapeutics International AB (OM:GUARD) in a reverse merger transaction in a transaction valued at SEK 61 million.	CI
05-11	Guard Therapeutics loss before and after tax SEK 6.4 mln	RE
05-11	Guard Therapeutics International AB Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-13	Seven stocks hit new 52-week lows on the Stockholm Stock Exchange so far today	FW
04-10	Three stocks hit new 52-week lows on the Stockholm Stock Exchange so far today	FW
03-31	Guard Therapeutics updates on strategic review	RE
03-31	Guard Therapeutics nears next phase of strategic review	FW

25-10-26	Guard Therapeutics Announces Top-Line Results from Phase 2b POINTER Study	CI
25-09-11	Redeye Initiates Coverage of Guard Therapeutics with Target Value of SEK 43	FW

07-27	Guard Therapeutics Completes Reverse Takeover of Disruptive Pharma and Executes In-Kind Share Issue	AQ
07-16	Guard Therapeutics Receives Conditional Approval for Continued Listing on Nasdaq First North Growth Market and Publishes Company Description	AQ
06-12	Guard Therapeutics Initiates Transaction Process for the GTX Platform	AQ
06-10	Guard Therapeutics has entered into a conditional agreement for a reverse takeover with Disruptive Pharma	AQ
04-09	Guard Therapeutics provides information regarding observation status on Nasdaq First North Growth Market	AQ

Disruptive Pharma AB Stock

Stocks

GUARD

SE0021181559

Biotechnology & Medical Research

Chart: Disruptive Pharma AB

Latest news : Disruptive Pharma AB

Last Transcript: Disruptive Pharma AB

Analysts' recommendations: Disruptive Pharma AB

Press Releases: Disruptive Pharma AB

News in other languages: Disruptive Pharma AB

Quotes and Performance

Course Extremes

Managers and Directors: Disruptive Pharma AB

Latest insider transactions

Other Biotechnology & Medical Research

Company Profile

Quotes

21-04-07	ERS Test AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß § 114, 115, 117 WpHG
21-04-07	ERS Test AG: Vorabbekanntmachung über die Veröffentlichung von Zahlungsberichten gemäß § 116 WpHG

1 day	+4.21%
1 week	-11.04%
Current month	-11.04%
1 month	-7.60%
3 months	+28.57%
6 months	-22.13%
Current year	-5.71%

1 week	1.25	1.45
1 month	1.25	1.8
Current year	0.88	2.35
1 year	0.88	27
3 years	0.88	49.8
5 years	0.88	112.5
10 years	0.88	3,050

Manager	Title	Age	Since
Tobias Larsson Agervald CEO	Chief Executive Officer	50	2019-01-14
Karin Botha DFI	Director of Finance/CFO	53	2020-09-13
Michael Reusch CTO	Chief Tech/Sci/R&D Officer	66	2021-12-31

Director	Title	Age	Since
Göran Forsberg BRD	Director/Board Member	63	2019-05-28
Johannes Hulthe BRD	Director/Board Member	56	2019-05-28
Johan Bygge CHM	Chairman	70	2021-04-30

Date	Insider	Type	Main position	Quantity	% Market Cap.
2/28/23	Tobias Larsson Agervald	Free	Chief Executive Officer	9,450,000	1.8784%
2/28/23	Karin Botha	Free	Chief Financial Officer	2,520,000	0.5009%
2/28/23	Peter Gilmour	Free		1,344,000	0.2672%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
DISRUPTIVE PHARMA AB	+4.21%	-11.04%	-93.97%	-83.50%	6.24M
LONZA GROUP AG	+0.99%	+1.78%	+4.07%	+16.73%	48.7B
REVOLUTION MEDICINES, INC.	+3.71%	+9.40%	+486.98%	+592.14%	42.05B
IQVIA HOLDINGS INC.	+2.70%	+1.57%	+33.39%	+8.85%	38.26B
BEONE MEDICINES AG	+5.60%	+10.21%	+16.76%	+85.72%	37.5B
CELLTRION, INC.	+2.21%	+6.75%	+21.31%	+53.37%	31.44B
ASCENDIS PHARMA A/S	+2.23%	+4.71%	-	-	16.47B
MEDPACE HOLDINGS, INC.	+0.97%	+2.35%	+37.75%	+126.84%	16.33B
EUROFINS SCIENTIFIC SE	-0.11%	+2.41%	+6.24%	+18.87%	13.98B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+0.75%	+15.04%	+78.59%	+30.30%	12.68B
Average	+2.33%	+3.43%	+65.68%	+94.37%	25.74B
Weighted average by Cap.	+2.52%	+5.04%	+103.56%	+139.73%